Resistance to PRMT5 Inhibitor Targeted Therapy in MCL [WES]
To identify the genomic changes underlying PRMT5 inhibitor resistance in MCL cell lines and MCL PDX Overall design: Whole exome of MCL PDX cells (untreated (n=1), short-term treated (n=1), and resistant treated (n=2)) and resistant and sensitive MCL cell lines